Recent Updates
Recently added Catalysts

Paxil

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials3
Total Enrollment216

FDA Designations

No designations recorded

Clinical trial landscape

Paxil · 3 trials · 1 indication

Phase 1 3
NCT00650403Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mgHealthy
COMPLETED66 Analytics
NCT00647881Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mgHealthy
COMPLETED75 Analytics
NCT00648427Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mgHealthy
COMPLETED75 Analytics
PHASE1COMPLETED
Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
HealthyUnlock trial analytics
PHASE1COMPLETED
Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg
HealthyUnlock trial analytics
PHASE1COMPLETED
Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALParoxetine hydrochloride 40 mg tablet
2ACTIVE_COMPARATORPaxil® 40 mg Tablet

Interventions

NameTypeDescription
Paroxetine hydrochloride 40 mg tabletDRUG40mg, single dose fed
Paxil® 40 mg TabletDRUG40mg, single dose fed
Paroxetine Hydrochloride Controlled-Release Tablets 25 mgDRUG25mg, single dose fed
Paxil CR™ Tablets 25 mgDRUG25mg, single dose fed
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Subjects who were informed of the nature of the study and agreed to read, review, and sign the informed consent document prior to Period I dosing. 2. Subjects who completed the screening process within 21 days prior to Period I dosing. 3. Subjects who were healthy adult men a...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Paxil

What is Paxil used for?

Paxil is an investigational small molecule being studied in healthy volunteers. The drug is in Phase 1 clinical development, with completed trials evaluating paroxetine hydrochloride formulations, including controlled-release 25 mg tablets and 40 mg tablets, compared to reference Paxil CR and Paxil products.

Who makes Paxil?

Paxil is being developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development, with trials conducted in the United States.

What phase is Paxil in?

Paxil is in Phase 1 clinical development. All three clinical trials listed for the drug are completed, with no active trials currently ongoing. The drug is investigational and has not been approved for any indication.

What clinical trials is Paxil in?

Paxil has three completed Phase 1 clinical trials: NCT00647881, a food study of paroxetine hydrochloride controlled-release 25 mg tablets versus Paxil CR 25 mg; NCT00648427, a fasting study of the same formulations; and NCT00650403, a food study of paroxetine hydrochloride 40 mg tablets versus Paxil 40 mg. All trials enrolled healthy adults in the United States.

Is Paxil the same as paroxetine?

Paxil is a brand name for paroxetine hydrochloride, a small molecule drug. The clinical trials listed for Paxil compare generic paroxetine hydrochloride formulations to the reference products Paxil CR and Paxil, indicating that Paxil refers to the branded paroxetine products.